Literature DB >> 22268458

Fatalities temporally associated with the ingestion of ibogaine.

Kenneth R Alper1, Marina Stajić, James R Gill.   

Abstract

Ibogaine is a naturally occurring psychoactive plant alkaloid that is used globally in medical and nonmedical settings for opioid detoxification and other substance use indications. All available autopsy, toxicological, and investigative reports were systematically reviewed for the consecutive series of all known fatalities outside of West Central Africa temporally related to the use of ibogaine from 1990 through 2008. Nineteen individuals (15 men, four women between 24 and 54 years old) are known to have died within 1.5-76 h of taking ibogaine. The clinical and postmortem evidence did not suggest a characteristic syndrome of neurotoxicity. Advanced preexisting medical comorbidities, which were mainly cardiovascular, and/or one or more commonly abused substances explained or contributed to the death in 12 of the 14 cases for which adequate postmortem data were available. Other apparent risk factors include seizures associated with withdrawal from alcohol and benzodiazepines and the uninformed use of ethnopharmacological forms of ibogaine.
© 2012 American Academy of Forensic Sciences.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22268458     DOI: 10.1111/j.1556-4029.2011.02008.x

Source DB:  PubMed          Journal:  J Forensic Sci        ISSN: 0022-1198            Impact factor:   1.832


  20 in total

Review 1.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

Review 2.  Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence.

Authors:  Kelly E Dunn; Andrew S Huhn; Cecilia L Bergeria; Cassandra D Gipson; Elise M Weerts
Journal:  J Pharmacol Exp Ther       Date:  2019-08-07       Impact factor: 4.030

Review 3.  The adverse events of ibogaine in humans: an updated systematic review of the literature (2015-2020).

Authors:  Genís Ona; Juliana Mendes Rocha; José Carlos Bouso; Jaime E C Hallak; Tre Borràs; Maria Teresa Colomina; Rafael G Dos Santos
Journal:  Psychopharmacology (Berl)       Date:  2021-08-18       Impact factor: 4.530

4.  Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report.

Authors:  Laurie Cloutier-Gill; Evan Wood; Trevor Millar; Caroline Ferris; M Eugenia Socias
Journal:  J Psychoactive Drugs       Date:  2016-05-18

Review 5.  Ibogaine-associated cardiac arrest and death: case report and review of the literature.

Authors:  Jessica A Meisner; Susan R Wilcox; Jeremy B Richards
Journal:  Ther Adv Psychopharmacol       Date:  2016-01-13

6.  Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study.

Authors:  Thomas Knuijver; Arnt Schellekens; Maarten Belgers; Rogier Donders; Toon van Oosteren; Kees Kramers; Robbert Verkes
Journal:  Addiction       Date:  2021-08-09       Impact factor: 7.256

Review 7.  The anti-addiction drug ibogaine and the heart: a delicate relation.

Authors:  Xaver Koenig; Karlheinz Hilber
Journal:  Molecules       Date:  2015-01-29       Impact factor: 4.411

8.  "Herbal seizures"--atypical symptoms after ibogaine intoxication: a case report.

Authors:  Lorenz Breuer; Burkhard S Kasper; Bernd Schwarze; Juergen M Gschossmann; Johannes Kornhuber; Helge H Müller
Journal:  J Med Case Rep       Date:  2015-10-31

Review 9.  The iboga enigma: the chemistry and neuropharmacology of iboga alkaloids and related analogs.

Authors:  Rishab N Iyer; David Favela; Guoliang Zhang; David E Olson
Journal:  Nat Prod Rep       Date:  2021-03-04       Impact factor: 13.423

10.  The developing utility of zebrafish models for cognitive enhancers research.

Authors:  Adam Michael Stewart; Allan V Kalueff
Journal:  Curr Neuropharmacol       Date:  2012-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.